ANDA SECURITY AGREEMENTSecurity Agreement • June 14th, 2017 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • New Jersey
THIS ABBREVIATED NEW DRUG APPLICATION SECURITY AGREEMENT (the “Agreement”), dated as of May 15, 2017, between Elite Laboratories, Inc., a Delaware corporation (“Elite”) and its parent, Elite Pharmaceuticals, Inc., a Nevada corporation (collectively, “Debtors”), and Mikah Pharma LLC, a limited liability company organized under the laws of the State of Delaware ("Secured Party");
ASSET PURCHASE AGREEMENTAsset Purchase Agreement • June 14th, 2017 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • New Jersey
ASSET PURCHASE AGREEMENT (“Agreement”), dated May 15, 2017 (the “Effective Date”), between Mikah Pharma LLC a limited liability company organized under the laws of the State of Delaware ( “Seller”) and Elite Laboratories, Inc., a corporation incorporated under the laws of the State of Delaware (“Buyer”). Buyer and Seller are each “Party” to this Agreement and together constitute the “Parties”.
MANUFACTURING AND SUPPLY AGREEMENTManufacturing Agreement • June 14th, 2017 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • Delaware
This MANUFACTURING AND SUPPLY AGREEMENT (this "Agreement") is made as of May _, 2011, (the "Effective Date") by and between Mikah Pharma, LLC, organized and existing under the laws of the State of Delaware, having offices at 20 Kilmer Drive, Hillsborough, New Jersey 08844, (referred to herein as "Mikah”) and Epic Pharma, LLC, a company organized under the laws of Delaware having offices at 227-15 N. Conduit Avenue, Laurelton, NY 11413 (referred to herein as "Epic" or "Manufacturer"). Mikah and Epic are each a "Party" and together constitute the "Parties" to this agreement
SUPPLY AND DISTRIBUTION AGREEMENTSupply and Distribution Agreement • June 14th, 2017 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • New Jersey
This SUPPLY AND DISTRIBUTION AGREEMENT (the “Agreement”), dated May 4, 2017 (the “Effective Date”), is by and between Dr. Reddy’s Laboratories Inc., organized and existing under the laws of New Jersey having an office at 107 College Road East, Princeton, New Jersey 08540 ("DRL") and Mikah Pharma, LLC, organized and existing under the laws of the State of Delaware, having an office at 20 Kilmer Drive, Hillsborough, New Jersey 08844 (“Mikah”). DRL and Mikah are each a “Party” and together constitute the “Parties” under this Agreement.
ASSIGNMENT AGREEMENTAssignment Agreement • June 14th, 2017 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • New Jersey
This assignment agreement (“Assignment Agreement”) is entered into as of May 22, 2017, by and between Mikah Pharma LLC (“Mikah”) organized and existing under the laws of Delaware having an office at 20 Kilmer Drive, Hillsborough, NJ 08844 (the “Mikah”), and Elite Laboratories, Inc. (“Elite”) organized and existing under the laws of Delaware having an office at 165 Ludlow Avenue, Northvale, NJ 07647. Capitalized terms used but not defined herein shall have the meanings ascribed to them in that certain Manufacturing and Supply Agreement between Mikah Pharma LLC and Epic Pharma, LLC at 227-15 N. Conduit Avenue, Laurelton, NY 11413 dated as of May 11, 2011 (the “Manufacturing Agreement”).
ASSIGNMENT AGREEMENTAssignment Agreement • June 14th, 2017 • Elite Pharmaceuticals Inc /Nv/ • Pharmaceutical preparations • New Jersey
This assignment agreement ( “Assignment Agreement”) is entered into as of May 17, 2017, by and between Mikah Pharma LLC (“Mikah”) organized and existing under the laws of Delaware having an office at 20 Kilmer Drive, Hillsborough, NJ 08844 (the “Mikah”), and Elite Laboratories, Inc. (“Elite”) organized and existing under the laws of Delaware having an office at 165 Ludlow Avenue, Northvale, NJ 07647. Capitalized terms used but not defined herein shall have the meanings ascribed to them in that certain Supply and Distribution Agreement between Mikah Pharma LLC and Dr. Reddy’s Laboratories, Inc. at 107 College Road East, Princeton, NJ 08540 dated as of May 4, 2017 (the “Distribution Agreement”).
